Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.

Gastroenterology | Mar 2, 2010

BACKGROUND & AIMS: Mutations in the DNA mismatch repair (MMR) gene MSH2 cause Lynch syndromes I and II and sporadic colorectal cancers. Msh2(null) mice predominantly develop lymphoma and do not accurately recapitulate the colorectal cancer phenotype. METHODS: We generated and examined mice with a conditional Msh2 disruption (Msh2(LoxP)), permitting tissue-specific gene inactivation. ECMsh2(LoxP/LoxP) mice carried an EIIa-Cre transgene, and VCMsh2(LoxP/LoxP) mice carried a Villin-Cre transgene. We combined the VCMsh2(LoxP) allele with either Msh2(Delta7null) (VCMsh2(LoxP/null)) or Msh2(G674D) mutations (VCMsh2(LoxP/G674D)) to create allelic phase mutants. These mice were given cisplatin or 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX), and their tumors were measured by magnetic resonance imaging. RESULTS: Embryonic fibroblasts from ECMsh2(LoxP/LoxP) mice do not express MSH2 and are MMR deficient. Reverse transcription, polymerase chain reaction, and immunohistochemistry from VCMsh2(LoxP/LoxP) mice demonstrated specific loss of Msh2 messenger RNA and protein from epithelial cells of the intestinal tract. Microsatellite instability was observed in all VCMsh2 strains and limited to the intestinal mucosa. Resulting adenomas and adenocarcinomas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene. VCMsh2(LoxP/LoxP) mice did not develop lymphoma. Comparison of allelic phase tumors revealed significant differences in multiplicity and size. When treated with cisplatin or FOLFOX, tumor size was reduced in VCMsh2(LoxP/G674D) but not VCMsh2(LoxP/null) tumors. The apoptotic response to FOLFOX was partially sustained in the intestinal mucosa of VCMsh2(LoxP/G674D) animals. CONCLUSIONS: Msh2(LoxP/LoxP) mice in combination with appropriate Cre recombinase transgenes have excellent potential for preclinical modeling of Lynch syndrome, MMR-deficient tumors of other tissue types, and use in drug development.

Pubmed ID: 19931261 RIS Download

Mesh terms: Adenocarcinoma | Adenoma | Animals | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Apoptosis | Cisplatin | Colorectal Neoplasms, Hereditary Nonpolyposis | Disease Models, Animal | Drug Resistance, Neoplasm | Fluorouracil | Gene Expression Regulation, Neoplastic | Gene Silencing | Genes, APC | Genotype | Immunohistochemistry | Integrases | Intestinal Neoplasms | Leucovorin | Magnetic Resonance Imaging | Mice | Mice, Inbred C57BL | Mice, Knockout | Microfilament Proteins | Microsatellite Instability | MutS Homolog 2 Protein | Mutation | Organoplatinum Compounds | Phenotype | Reverse Transcriptase Polymerase Chain Reaction | Time Factors | Tumor Burden

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, Id: R01 CA093484-08
  • Agency: NIEHS NIH HHS, Id: ES11040
  • Agency: NCI NIH HHS, Id: U01 CA084301
  • Agency: NCI NIH HHS, Id: P30 CA013330-37S49022
  • Agency: NCI NIH HHS, Id: CA13330
  • Agency: NCI NIH HHS, Id: R01 CA093484
  • Agency: NIEHS NIH HHS, Id: Z01 ES065089
  • Agency: NCI NIH HHS, Id: R01 CA076329
  • Agency: Intramural NIH HHS, Id: Z01 ES065089-12
  • Agency: NIEHS NIH HHS, Id: U01 ES011040-06
  • Agency: NCI NIH HHS, Id: U01 CA084301-11
  • Agency: NCI NIH HHS, Id: CA084301
  • Agency: NIEHS NIH HHS, Id: U01 ES011040
  • Agency: NCI NIH HHS, Id: CA93484
  • Agency: NCI NIH HHS, Id: P30 CA013330
  • Agency: NCI NIH HHS, Id: R01 CA076329-12
  • Agency: NCI NIH HHS, Id: CA76329

Mouse Genome Informatics (Data, Gene Annotation)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.